Advertisement

Topics

Finch Therapeutics Group, Inc. Company Profile

18:49 EST 19th January 2019 | BioPortfolio

Finch Therapeutics Group is developing novel microbial therapies to serve patients with serious unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses innovative machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience, building upon the science of fecal transplantation. Finch uses this human-first discovery approach to identify strains that drive clinical outcomes, developing therapies that deliver these microbial communities to patients. Through a strategic merger with Crestovo in 2017, Finch established a leading position in addressing the C. difficile epidemic with Crestovo’s lead Full-Spectrum Microbiota™ product, CP101, which is currently being evaluated among patients suffering from recurrent C. difficile infections.


News Articles [1435 Associated News Articles listed on BioPortfolio]

Filgotinib meets in Phase III FINCH 2 study for RA

Melinta Therapeutics and Menarini Group Enter Commercial Agreement

Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian bioph...

IP Group: Avacta Signs Development Alliance With LG Chem Worth Up To $310 Mln

LONDON (dpa-AFX) - IP Group plc (IPO.L) , a developer of intellectual property-based businesses, announced Monday that portfolio company Avacta Group plc has agreed an Affimer therapeutics develop...

Avacta Group PLC signs first significant pharmaceutical licensing deal

Alastair Smith, chief executive of Avacta Group PLC (LON:AVCT), discusses with Proactive London an Affimer therapeutics development partnership and license agreement that's been signed with LG Chem ...

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

-- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life – Gilead Sciences, Inc. (Nasdaq: GILD...

SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunother...

FINCH-2 data bodes well for Gilead, Galapagos JAK inhibitor

The rheumatoid arthritis study showed no patients taking filgotinib experienced deep venous thrombosis, a key concern leading up to Tuesday's readout.

Summit Therapeutics plc: Director/PDMR Shareholding

Summit Therapeutics plc ('Summit', the 'Company', or the 'Group')Director / PDMR Share DealingOxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces ...

PubMed Articles [2237 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Omega-3 fatty acid supplements do not improve symptoms of dry eye disease.

: The Dry Eye Assessment and Management Study Research Group. N-3 fatty acid supplementation for the treatment of dry eye disease. 2018;378:1681-90.

Clinical Trials [4376 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

This study is designed to assess the safety, tolerability and engraftment (cumulative relative abundance) of MET-4 strains when given in combination with immune checkpoint inhibitors (ICIs...

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [2954 Associated Companies listed on BioPortfolio]

Lava Therapeutics

Lava Therapeutics’ proprietary platform is focused on developing next generation γδ T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-onc...

Xenova Group PLC

Xenova Group plc is an emerging pharmaceutical group, specialising in the development of new small molecule drugs. The company’s strategy is to develop commercially attractive new drugs, primarily i...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Finch Therapeutics Group, Inc." on BioPortfolio

We have published hundreds of Finch Therapeutics Group, Inc. news stories on BioPortfolio along with dozens of Finch Therapeutics Group, Inc. Clinical Trials and PubMed Articles about Finch Therapeutics Group, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Finch Therapeutics Group, Inc. Companies in our database. You can also find out about relevant Finch Therapeutics Group, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Clostridium difficile (CDI)
A clostridium difficile infection (CDI) is a type of bacterial infection that can affect the digestive system. It most commonly affects people who are staying in hospital.  The symptoms of CDI can range from mild to severe and include: diarrhoe...


Corporate Database Quicklinks



Searches Linking to this Company Record